Market Exclusive

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) had its Buy rating reiterated by Evercore ISI with a $55.00 price target

Analyst Ratings For Adamas Pharmaceuticals Inc (NASDAQ:ADMS)

Today, Evercore ISI reiterated its Buy rating on Adamas Pharmaceuticals Inc (NASDAQ:ADMS) with a price target of $55.00.

There are 5 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is Hold with a consensus target price of $25.1250 per share, a potential 315.29% upside.

Some recent analyst ratings include

Recent Trading Activity for Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
Shares of Adamas Pharmaceuticals Inc closed the previous trading session at 6.05 −0.070 1.14% with 4.87 shares trading hands.

Exit mobile version